◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Himadri Speciality Chemical Limited (HSCL) Revenue 2022–TTM

Name: Himadri Speciality Chemical Limited (HSCL) revenue history 2022-TTM
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-11-02

Himadri Speciality Chemical Limited annual revenue for fiscal TTM was ₹55.9 billion, an increase of 20.1% from ₹46.6 billion in fiscal 2026. All figures are reported results from public filings — no estimates or projections.

HSCL Annual Revenue

Revenue (annual)	TTM → 2026-09-30	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Total Revenue	₹55.9B	₹46.6B	₹46.0B	₹41.8B	₹41.7B	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

HSCL Quarterly Revenue

Revenue (quarterly)	2026-09-30	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30
Total Revenue	₹16.9B	₹14.3B	₹12.9B	₹11.8B	—	₹11.2B

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Revenue at Comparable Companies

ACUTAAS Revenue — Acutaas Chemicals Limited
7966 Revenue — LINTEC Corporation
4966 Revenue — C.Uyemura & Co.,Ltd.
4043 Revenue — Tokuyama Corporation
4634 Revenue — artience Co., Ltd.
8098 Revenue — Inabata & Co.,Ltd.

More HSCL metrics: Gross Profit · Operating Income · Net Income · EPS · Free Cash Flow

All HSCL financial statements → Interactive HSCL charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.